Content
FDA approved for more than 25 years
Hair loss can drive anyone down an online research rabbit hole, and if you’ve gone deep enough into those search results, you may have seen someone mention clobetasol propionate for hair loss. But does this topical corticosteroid actually work for that purpose?
The answer is complicated. Officially, yes, clobetasol can manage certain types of hair loss, but it’s prescribed in an off-label capacity for these limited circumstances. And chances are that the type of hair loss clobetasol is for (alopecia areata) isn’t what you’re looking to manage.
Below, we’ve explained what clobetasol does, what hair loss conditions it can and cannot manage, and whether you should ask a health professional about using clobetasol for hair loss.
Content
Clobetasol (the generic of ClobexⓇ) is a prescription corticosteroid, a high-potency immunosuppressive medication sometimes prescribed for the treatment of hair loss. Several different doses of the topical steroid clobetasol have been shown to effectively manage alopecia areata — a type of hair loss caused by an autoimmune disorder.
Officially, however, clobetasol is not a hair regrowth medication at all. In fact, the FDA has not approved this topical corticosteroid for use in hair loss, even in circumstances of alopecia areata.
But because clobetasol is FDA-approved for the management of certain skin conditions like eczema, scarring alopecia, psoriasis, and plaque psoriasis, some experts have figured out that it also appears to be effective in in the treatment of alopecia areata in adults and in children who are 2 years of age and up.
Indeed, several small studies have confirmed that clobetasol for alopecia areata could be an effective option, though more research and further clinical trials are needed.
Depending on the type of hair loss you’re diagnosed with, topical application of this medication could repress the harmful effects of the immune system in its attempts to mistakenly attack and kill your hair fibers (which is how autoimmune diseases lead to hair loss).
If you believe you’re dealing with alopecia areata, a dermatologist or other healthcare professional can discuss clobetasol as one of your potential hair loss treatment options. However, most experts agree that for androgenic alopecia — also known as male pattern baldness — this medication is not effective.
The primary reason that clobetasol works for autoimmune hair loss but not for genetic and hormonal hair loss is that clobetasol manages inflammation, not hormones.
While autoimmune conditions can cause inflammation that eventually smothers your follicles, male pattern baldness kills follicles of hair by weakening them with a testosterone variant called dihydrotestosterone, or DHT.
Hair loss due to DHT is not manageable with corticosteroids.
If you are experiencing alopecia areata, you will need a prescription to access this medication., since clobetasol is more potent than popular topical steroids like triamcinolone acetonide and hydrocortisone.
Generally, side effects from clobetasol are mild, and the topical treatment is typically well-tolerated on the skin.
Side effects most commonly include:
Redness
Folliculitis
Dryness
Pain
Pigmentation changes
To use topical clobetasol, you spread a thin layer over the surface area affected by hair loss. Follow the directions for the product you’re using — a spray will have different application guidelines than lotion preparations. Following these guidelines will help minimize your risk of adverse effects.
You should not use clobetasol if you have skin conditions like dermatitis or skin atrophy present at the site. Clobetasol can cause irritation to the skin and hair follicles.
If you experience any side effects, share them with your healthcare provider, and discontinue use if they become severe.
Clobetasol for hair loss could work, but only if you have hair loss caused by an autoimmune condition, such as alopecia areata. In these instances, clobetasol can help to manage inflammation that can negatively affect hair growth. However, more research is needed to confirm the prospect of clobetasol for alopecia areata, and the topical corticosteroid is unlikely to work for other types of hair loss, such as male pattern baldness.
To recap, here’s what to know about clobetasol propionate topical solution for hair loss:
Clobetasol may help individuals with specific and autoimmune types of hair loss, but the medication is not FDA-approved for this purpose and must be prescribed off-label.
Dermatology experts will generally want to discuss your symptoms before prescribing medications to make sure that you’re being properly diagnosed and treated. They will also want to know what other medications and supplements you’re currently taking, to avoid risk of drug interactions.
For androgenic alopecia, which is not treatable with clobetasol, experts generally recommend using topical minoxidil foam or minoxidil solution, both of which are approved by the FDA for the treatment of various hair loss types including male pattern baldness. Minoxidil can be especially effective along with finasteride, which is also FDA-approved for the treatment of hair loss. You can get both options at once in formulations like our topical finasteride & minoxidil spray
If you’re ready to get diagnosed and treat the problem — autoimmune or otherwise — reach out today.
Hims & Hers has strict sourcing guidelines to ensure our content is accurate and current. We rely on peer-reviewed studies, academic research institutions, and medical associations. We strive to use primary sources and refrain from using tertiary references. See a mistake? Let us know at [email protected]!
Dr. Knox Beasley is a board certified dermatologist specializing in hair loss. He completed his undergraduate studies at the United States Military Academy at West Point, NY, and subsequently attended medical school at Tulane University School of Medicine in New Orleans, LA.
Dr. Beasley first began doing telemedicine during his dermatology residency in 2013 with the military, helping to diagnose dermatologic conditions in soldiers all over the world.
Dr. Beasley is board certified by the American Board of Dermatology, and is a Fellow of the American Academy of Dermatology.
Originally from Nashville, TN, Dr. Beasley currently lives in North Carolina and enjoys spending time outdoors (with sunscreen of course) with his wife and two children in his spare time.
Bachelor of Science, Life Sciences. United States Military Academy.
Doctor of Medicine. Tulane University School of Medicine
Dermatology Residency. San Antonio Uniformed Services Health Education Consortium
Board Certified. American Board of Dermatology
Wilson, L. M., Beasley, K. J., Sorrells, T. C., & Johnson, V. V. (2017). Congenital neurocristic cutaneous hamartoma with poliosis: A case report. Journal of cutaneous pathology, 44(11), 974–977. https://onlinelibrary.wiley.com/doi/10.1111/cup.13027
Banta, J., Beasley, K., Kobayashi, T., & Rohena, L. (2016). Encephalocraniocutaneous lipomatosis (Haberland syndrome): A mild case with bilateral cutaneous and ocular involvement. JAAD case reports, 2(2), 150–152. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867906/
Patterson, A. T., Beasley, K. J., & Kobayashi, T. T. (2016). Fibroelastolytic papulosis: histopathologic confirmation of disease spectrum variants in a single case. Journal of cutaneous pathology, 43(2), 142–147. https://onlinelibrary.wiley.com/doi/10.1111/cup.12569
Beasley, K., Panach, K., & Dominguez, A. R. (2016). Disseminated Candida tropicalis presenting with Ecthyma-Gangrenosum-like Lesions. Dermatology online journal, 22(1), 13030/qt7vg4n68j. https://pubmed.ncbi.nlm.nih.gov/26990472/
Kimes, K., Beasley, K., & Dalton, S. R. (2015). Eruptive milia and comedones during treatment with dovitinib. Dermatology online journal, 21(9), 13030/qt8kw141mb. https://pubmed.ncbi.nlm.nih.gov/26437285/
Miladi, A., Thomas, B. C., Beasley, K., & Meyerle, J. (2015). Angioimmunoblastic t-cell lymphoma presenting as purpura fulminans. Cutis, 95(2), 113–115. https://pubmed.ncbi.nlm.nih.gov/25750965/
Beasley K, Dai JM, Brown P, Lenz B, Hivnor CM. (2013). Ablative Fractional Versus Nonablative Fractional Lasers – Where Are We and How Do We Compare Differing Products?. Curr Dermatol Rep, 2, 135–143. https://idp.springer.com/authorize?response_type=cookie&client_id=springerlink&redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs13671-013-0043-0
Siami P, Beasley K, Woolen S, Zahn J. (2012). A retrospective study evaluating the efficacy and tolerability of intra-abdominal once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. UroToday Int J, June 5(3), art 26. https://www.urotoday.com/volume-5-2012/vol-5-issue-3/51132-a-retrospective-study-evaluating-the-efficacy-and-tolerability-of-intra-abdominal-once-yearly-histrelin-acetate-subcutaneous-implants-in-patients-with-advanced-prostate-cancer.html
Siami P, Beasley K. (2012). Dutasteride with As-Needed Tamsulosin in Men at Risk of Benign Prostate Hypertrophy Progression. UroToday Int J, Feb 5(1), art 93. https://www.urotoday.com/volume-5-2012/vol-5-issue-1/48691-dutasteride-with-as-needed-tamsulosin-in-men-at-risk-of-benign-prostatic-hypertrophy-progression.html